Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.

ABSTRACT:

Background

Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment.

Objective

To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD.

Methods

Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks. Respiratory parameters and plasma levels of multiple eicosanoids were recorded at baseline and after 4 weeks of aspirin therapy using the Asthma Control Test and Rhinoconjunctivitis Quality of Life Questionnaire. Respiratory function was evaluated using the FEV₁ and nasal inspiratory peak

SUBMITTER: Jerschow E 

PROVIDER: S-EPMC5491381 | biostudies-literature | 2017 Jul - Aug

REPOSITORIES: biostudies-literature